On February 3, 2023, the Department of Justice Antitrust Division (DOJ) announced the withdrawal of three policy statements that have long guided the information exchanges as well as the related enforcement in the healthcare space.1 The DOJ noted that these statements were “outdated,” “overly permissive,” and no longer demonstrated “modern market realities.” The DOJ indicated that the removal of the statements would best promote competition and transparency and claimed that enforcement on a case-by-case basis […]

We previously reported on Regeneron’s antitrust suit against Amgen in the U.S. District Court for the District of Delaware. The case concerns Regeneron’s allegation that Amgen has violated antitrust law by engaging “in a persistent exclusionary campaign to deny patients the life-saving benefits of [] Regeneron’s cholesterol-reducing medication, Praluent® (alirocumab).” According to Regeneron, the reason for Amgen’s campaign “is simple: for years, Praluent® has been the only direct competitor to Amgen’s own drug Repatha® (evolocumab) and […]